1. Home
  2. AFMD vs LGCL Comparison

AFMD vs LGCL Comparison

Compare AFMD & LGCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • LGCL
  • Stock Information
  • Founded
  • AFMD 2000
  • LGCL 2009
  • Country
  • AFMD Germany
  • LGCL China
  • Employees
  • AFMD N/A
  • LGCL 361
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • LGCL
  • Sector
  • AFMD Health Care
  • LGCL
  • Exchange
  • AFMD Nasdaq
  • LGCL NYSE
  • Market Cap
  • AFMD 45.6M
  • LGCL 44.3M
  • IPO Year
  • AFMD 2014
  • LGCL 2024
  • Fundamental
  • Price
  • AFMD $1.27
  • LGCL $0.51
  • Analyst Decision
  • AFMD Strong Buy
  • LGCL
  • Analyst Count
  • AFMD 5
  • LGCL 0
  • Target Price
  • AFMD $13.50
  • LGCL N/A
  • AVG Volume (30 Days)
  • AFMD 498.2K
  • LGCL 481.8K
  • Earning Date
  • AFMD 11-14-2024
  • LGCL 11-22-2024
  • Dividend Yield
  • AFMD N/A
  • LGCL N/A
  • EPS Growth
  • AFMD N/A
  • LGCL 11.49
  • EPS
  • AFMD N/A
  • LGCL 0.14
  • Revenue
  • AFMD $6,287,085.00
  • LGCL $173,306,912.00
  • Revenue This Year
  • AFMD N/A
  • LGCL N/A
  • Revenue Next Year
  • AFMD $28.44
  • LGCL N/A
  • P/E Ratio
  • AFMD N/A
  • LGCL $4.05
  • Revenue Growth
  • AFMD N/A
  • LGCL N/A
  • 52 Week Low
  • AFMD $1.40
  • LGCL $0.51
  • 52 Week High
  • AFMD $8.95
  • LGCL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 16.00
  • LGCL N/A
  • Support Level
  • AFMD $1.40
  • LGCL N/A
  • Resistance Level
  • AFMD $2.21
  • LGCL N/A
  • Average True Range (ATR)
  • AFMD 0.24
  • LGCL 0.00
  • MACD
  • AFMD -0.08
  • LGCL 0.00
  • Stochastic Oscillator
  • AFMD 3.33
  • LGCL 0.00

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.

Share on Social Networks: